Biosense Webster Develops First AF Ablation Catheter Following Atrionix Buy

J&J/Cordis' $62.8 mil. cash acquisition of Atrionix rounds out Biosense Webster's electrophysiology product line with a catheter-based ablation approach to atrial fibrillation (AF).

More from Archive

More from Medtech Insight